Literature DB >> 21199210

Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.

Claire Irving1, Vaughan Carter, Gareth Parry, Asif Hasan, Richard Kirk.   

Abstract

There is increasing evidence that DSA are associated with poor graft survival, although there are little data in children. We aimed to describe the incidence of DSA in this group and to determine correlation with graft survival. HLA antibodies were analysed in 59 paediatric cardiac transplant recipients. Mean age 10.4 (0.7-18.5) yr, mean time post-transplant 5.1 (0.3-17.3) yr. Antibody detection/identification was performed on the Luminex platform with subsequent identification using Lifescreen Identification kits/One-Lambda Single antigen kits. Forty patients (69%) had no HLA antibodies. DSA were found in four (7%). One had transient Class I antibodies and normal cardiac function. The other three had persistent Class II antibodies (two subsequently required re-transplantation, the third had cardiac failure due to CAV). Non-DSA were found in 15 (25%), all with normal graft function and without rejection. There was no difference in function or CAV prevalence between those with non-DSA and those without antibodies. HLA DSA is uncommon in paediatric cardiac allograft recipients but, if persistent, suggests poorer prognosis. In our series, antibodies to HLA class II on donor tissue were associated with increased graft loss. Routine screening and regular testing are recommended.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199210     DOI: 10.1111/j.1399-3046.2010.01446.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  5 in total

1.  Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.

Authors:  Warren A Zuckerman; Adriana Zeevi; Kristen L Mason; Brian Feingold; Carol Bentlejewski; Linda J Addonizio; Elizabeth D Blume; Charles E Canter; Anne I Dipchand; Daphne T Hsu; Robert E Shaddy; William T Mahle; Anthony J Demetris; David M Briscoe; Thalachallour Mohanakumar; Joseph M Ahearn; David N Iklé; Brian D Armstrong; Yvonne Morrison; Helena Diop; Jonah Odim; Steven A Webber
Journal:  Am J Transplant       Date:  2018-03-23       Impact factor: 8.086

2.  Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study.

Authors:  A I Dipchand; S Webber; K Mason; B Feingold; C Bentlejewski; W T Mahle; R Shaddy; C Canter; E D Blume; J Lamour; W Zuckerman; H Diop; Y Morrison; B Armstrong; D Ikle; J Odim; A Zeevi
Journal:  Am J Transplant       Date:  2018-03-24       Impact factor: 8.086

Review 3.  Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.

Authors:  Antonietta Picascia; Vincenzo Grimaldi; Amelia Casamassimi; Maria Rosaria De Pascale; Concetta Schiano; Claudio Napoli
Journal:  J Cardiovasc Transl Res       Date:  2014-09-05       Impact factor: 4.132

4.  An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA.

Authors:  K A Thomas; N M Valenzuela; D Gjertson; A Mulder; M C Fishbein; G C Parry; S Panicker; E F Reed
Journal:  Am J Transplant       Date:  2015-04-22       Impact factor: 8.086

Review 5.  Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.

Authors:  Massimo Mangiola; Marilyn Marrari; Brian Feingold; Adriana Zeevi
Journal:  Front Immunol       Date:  2017-01-27       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.